At the opening plenary of EBMT 2025, Dr. Luca Vago (Italy) delivered a thought-provoking presentation on the biological complexity behind leukemia relapse after allogeneic hematopoietic cell transplantation (allo-HCT).
Key insights from the session:
- Allo-HCT is a highly complex immunobiological system, where variables such as donor type or antiviral use can unexpectedly influence outcomes
- There is a critical need to rethink the design of clinical trials—shifting from broad indications to biologically defined subgroups with more personalized timing of intervention
- Leveraging real-world data and artificial intelligence (AI) could better define relapse risk factors, enabling earlier interventions and potentially preventing clinical recurrence
Dr. Vago emphasized that future strategies must integrate biology, timing, and data-driven personalization to break the cycle of post-transplant relapse in leukemia.
A brilliant contribution to the evolving landscape of precision transplant medicine.
